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the original work isObjective: To determine whether tenofovir disoproxil fumarate (TDF)-associated renal
tubular dysfunction is associated with evidence of mitochondrial injury in urine.
Design: Single-centre cross-sectional observational study of HIV-positive outpatients.
Methods: Biochemistry was performed on paired serum and urine samples. Mitochon-
drial DNA (mtDNA) was studied by real-time PCR and long-range PCR on cellular
fractions of urine.
Results: In total, 48 study participants were enrolled of whom half were TDF treated.
Mean agewas 43 years. 58% had estimated glomerular filtration rate at least 90, with no
differences between ART treatment groups. Urinary phosphate wasting was common
and independently associated with TDF exposure (P¼0.02). No study participants had
low molecular weight proteinuria. Cellular mtDNA content in urine was heavily
influenced by the cellularity of the sample. The mtDNA ‘common deletion’ mutation
was detectable significantly more commonly in the urine of TDF exposed study
participants compared with unexposed (13/22 TDFþ study participants (59%), 4/21
TDF (19%), P¼0.01). Common deletion levels were not associated with age,
estimated glomerular filtration rate, or urinary phosphate wasting. NomtDNAmeasures
were associated with current or nadir CD4þ lymphocyte counts, duration of disease or
antiretroviral therapy, or historical exposure to nucleoside analogue reverse transcrip-
tase inhibitors with systemic mitochondrial toxicity.
Conclusion: The presence of mtDNA mutations in the context of TDF exposure adds
weight to the hypothesis that TDF-associated renal damage is at least in part mito-
chondrially mediated. The assessment of mtDNA markers in urine may be a feasible
noninvasive investigation for TDF-treated patients.
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Tenofovir disoproxil fumarate (TDF) is a first-line
antiretroviral drug globally. Generally, it is well tolerated;
however, a minority of patients develop renal compli-
cations. These can manifest either as deterioration of
estimated glomerular filtration rate (eGFR) or as proximal
tubulopathy leading to renal Fanconi syndrome [1,2].
TDF-associated renal tubular pathology is thought to
arise from the fact that the active metabolite of tenofovir
becomes concentrated within the cells of the proximal
tubule. Thus toxicity that does not manifest systemically
may nevertheless affect proximal tubular function. Many
of the older nucleoside analogue reverse transcriptase
inhibitor (NRTI) antiretroviral drugs caused systemic
mitochondrial toxicity through inhibition of the sole
mitochondrial DNA (mtDNA) polymerase, pol g,
leading to mtDNA depletion (for example, zidovudine,
stavudine, didanosine, zalcitabine) [3,4]. Subsequent
work from our group and others has shown that these
drugs may also cause mtDNA mutations. One of the
commonest mtDNAmutations is known as the ‘common
deletion’. This is a 4977 bp large-scale deletion in the
major arc of the mitochondrial genome, occurring
between two homologous 13 bp repeat sequences.
Sporadic occurrences of the common deletion in the
germline lead to Kearns-Sayre syndrome, but the
common deletion has also been detected as a common
somatic mutation which accumulates during ageing in a
variety of tissues [5–8]. The common deletion has also
been detected in the context of NRTI therapy [9].
Previous studies have suggested that TDF does not cause
mtDNA depletion in standard cell lines in vitro or in
preclinical animal testing [10,11]. However, studies of
rodents exposed to TDF have shown mtDNA depletion
that is specific to the kidney [12,13], and a human study of
patients undergoing renal biopsy for TDF-induced renal
toxicity showed ultrastructural mitochondrial abnorm-
alities on electron microscopy [14]. Although renal biopsy
is the gold standard for defining pathology, it is not
feasible for widespread clinical use in patients with mild or
subclinical toxicity. Recent work in inherited mtDNA
defects has shown that they can often be detected in the
urine of affected patients [15].
We, therefore, hypothesised that evidence of mitochon-
drial damage would be detectable in the urine of TDF-
treated HIV-infected patients. If true, this would confirm
that TDF can cause renal-specific mitochondrial toxicity,
and provide a putative noninvasive marker for the clinical
investigation of TDF-treated patients.Methods
All study participants gave written informed consent for
participation in the study. The study was approved by the Copyright © 2017 Wolters Kluwer HResearch Ethics Committee. This was a single-centre
cross-sectional study of HIV-infected adults attending for
outpatient HIV care. Consecutive study participants were
enrolled without selection for the presence or absence or
renal toxicity. Study participants with severe impairment
of renal function [(eGFR, CKD-EPI, chronic kidney
disease epidemiology collaboration)< 30] were excluded.
Demographic, clinical, and treatment data were obtained
by case note review.
Paired serum and urine samples (random/unfasted) were
collected for renal biochemistry. Phosphate wasting was
expressed as tubular maximum resorption of phosphate/
GFR (TmP to GFR; lower limit of normal 0.8–
1.0mmol/l depending on age and sex) [16]. Urate
wasting was calculated as fractional excretion of urate
(the percentage of urine to plasma urate normalized
to creatinine; upper limit of normal 10%). Tubular
proteinuria was assessed by urinary retinol-binding
protein (normal range 0–15mg/l).
An additional urine sample (40ml) was collected for
mtDNA analyses. This was centrifuged to pellet the
cellular content and total nucleic acid extraction was
performed from 200ml of pellet (NucliSENS easyMag,
bioMerieux, Marcy l’Etoile, France) into a 55ml elution
volume.
Real-time PCR (qPCR) was performed on a CFX
platform (Bio-Rad, Hercules, California, USA). A target
in MT-ND1 was used to quantify mtDNA content
(primers/probe: 50-ACGCCATAAAACTCTTCACC-
AAAG-30, 50-GGGTTCATAGTAGAAGAGCGATGG-
30, 50-HEX-ACCCGCCACATCTACCATCACCCTC-
BHQ1–30). The 4977 bp mtDNA ‘common deletion’
mutation was detected by an allele-specific qPCR assay
(primers/probe: 50-CCCACCATAATTACCCCCAT-
AC-30, 50-GGAGTAGAAACCTGTGAGGAAAGG-30,
50-Cy5-CCTACCTCCCTCACCATTGG-BHQ2–30).
Cell content was quantified by a target in b2M (primers/
probe: 50-CACTGAAAAAGATGAGTATGCC-30, 50-
AACATTCCCTGACAATCCC-30, 50-FAM-CCGT-
GTGAACCATGTGACTTTGTC-BHQ1–30). qPCR
was performed in 20ml reaction volumes comprising
1 iQ Multiplex Powermix (Bio-Rad), 300 nmol/l
common deletion and b2M primers, 75nmol/l MT-
ND1 primers, 200 nmol/l probes, and 2ml DNA. Cycling
conditions were: 958C for 3min, followed by 40 cycles of
958C for 10 s, and 62.58C for 1min. qPCR reactions were
performed in triplicate.
Long-range PCR was performed on a Veriti thermo-
cycler (Applied Biosystems, Foster City, California, USA)
in a 25ml reaction comprising: 1PrimeSTAR GXL
DNA buffer (Takara, Clontech Mountain View, Cali-
fornia, USA), 200mmol/l dNTP mix, 200 nmol/l
primers and 1.25U GXL polymerase (Takara, Clontech)
with 1–5ml DNA. Primers were: 50-CCCTCTCTCC-ealth, Inc. All rights reserved.
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Table 1. Study participants characteristics.
TDF ART (all, 24) Non-TDF ART (11) ART Naive (13) TDFþCDþ (13) TDFþCD (9)
Age (years) 45.310.3 46.614.3 36.511.7 47.510.1 45.19.7
Male 16 (67%) 7 (64%) 12 (92%) 10 (77%) 5 (56%)
Time since HIV diagnosis (months) 14972 204110 1823 14139 175104
Time on treatment (months) 11753 16196 12538 12362
Time on TDF (months) 4932 6329 3229
Current CD4þ cell count (cells/ml) 637337 570237 464251 608296 729400
HIV-1 RNA viral load (<50 c/ml) 23 (96%) 8 (73%) 13 (100%) 8 (89%)
Nadir CD4þ cell count (cells/ml) 13598 172112 410230 11686 168120
Black African ethnicity 8 (33%) 3 (27%) 0 2 (15%) 5 (56%)
Current smokers 7 (29%) 3 (27%) 5 (39%) 4 (36%) 2 (25%)
Documented osteoporosis 0 1 (9%) 0 0 0
Hepatitis C coinfection 2 (8%) 1 (9%) 0 1 (8%) 1 (11%)
Type 2 diabetes mellitus 2 (8%) 2 (18%) 1 (8%) 1 (8%) 1 (11%)
Hypertension 3 (13%) 2 (18%) 0 1 (8%) 1 (11%)
eGFR (CKD-EPI) 9321 9321 10118 9117 9124
TmP/GFR (mmol/l) 0.820.28 1.030.30 1.020.23 0.860.29 0.750.31
FEUa (%) 9.13.3 8.35.3 8.76.6 9.22.5 8.34.4
UPCR (mg/mmol)a 11.54.1 13.88.4 14.911.2 11.45.0 12.22.2
RBP (mg/l) 0.62.1 0 0 0.31.1 1.13.2
Where shown, values are mean SD. In two TDF-treated study participants molecular data was not able to be included. ART, antiretroviral
therapy; TDF, tenofovir disoproxil fumarate; CDþ/CD, mtDNA ‘common deletion’ detected/not detected; eGFR, estimated glomerular filtration
rate; TmP, tubular maximum resorption of phosphate; FEUa, fractional excretion of urate; UPCR, urinary protein:creatine ratio; RBP, urinary retinol
binding protein.
aOne TDF-treated case with nontubular proteinuria was excluded.TACTCCTG-30, 50-CAGGTGGTCAAGTATTTAT-
GG-30. The reaction generates a 10 kb product in
the presence of undeleted (full-length) mtDNA.Results
Study participant characteristics and renal
biochemistry
We enrolled 48 study participants. Mean age was 43 years
and 35 (73%) were male. Twenty-four study participants
(50%) were receiving TDF-based antiretroviral therapy
(ART). Of the 24 study participants not receiving TDF,
11 were on other ART and 13 were ART naive. Study
participants characteristics are shown in Table 1. Among
study participants taking TDF, 12 (50%) were on boosting
agents (11 ritonavir, one cobicistat). In total, 20 study
participants had been exposed to one or more pol g
inhibitingNRTIs at some point in their treatment history.
eGFR did not differ between groups. Measures of
proximal renal tubular function were also similar with the
exception of urinary phosphate wasting. Mean TmP/
GFR ( SD) was significantly lower in TDF-treated
study participants compared with unexposed (TDFþ
0.82 0.28, TDF 1.02 0.26, P¼ 0.02). Low TmP/
GFR correlated strongly with serum hypophosphataemia
(r 0.78, P< 0.001) and all study participants with
hypophosphataemia had low TmP/GFR, implying that
urinary phosphate wasting was a major driver of
hypophosphataemia. The majority of study participants
with evidence of both urinary phosphate and urate
wasting (low TmP/GFR and high fractional excretion of
urate) were TDF treated (TDFþ 8/22, 36%; TDF 2/21,
10%; P¼ 0.04). Copyright © 2017 Wolters KluwemtDNA analyses
In total, 43 study participants had analysable mtDNA
data. Urine is a highly heterogeneous tissue which may
vary widely in cellular composition between individuals.
As such, we observed no difference in urine mtDNA
depletion between ART groups (log10 mtDNA copies/
cell SD, TDFþ 2.75 0.73, TDF 2.61 0.81,
P¼ 0.6, Fig. 1a). Full details of mtDNA depletion
analyses are shown in supplementary online material,
http://links.lww.com/QAD/B67.
The mtDNA ‘common deletion’ was detectable in
17/43 urine samples (40%). Among cases with common
deletion detected mean level of the common deletion
mutation ( SD) was 3.86 0.77 log10 common
deletion per mtDNA genome copy. Presence of common
deletion was significantly associated with TDF exposure
(common deletion detected in 13/22 TDF-treated study
participants (59%) compared with 4/21 TDF unexposed
(19%, P¼ 0.01) Fig. 1b). Among TDF-treated study
participants, mean duration of TDF exposure was
significantly longer in those study participants with
detectable common deletion (common deletionþ
63 29 months, common deletion 32 29,
P¼ 0.02). Of note, detectability of common deletion
was not confounded by the cellular content of urine.
Presence of common deletion did not vary with past
exposure to NRTIs with systemic mitochondrial toxicity
[8/19 exposed study participants showed common
deletion detectable (42%), compared with 9/24 unex-
posed study participants (38%)]. There was no association
with study participant age (common deletionþ study
participants 46.2 11.0 years, common deletion
42.5 13.1 years, P¼ 0.3), current CD4þ lymphocyter Health, Inc. All rights reserved.
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Fig. 1. (a) mtDNA content in urine. (b) mtDNA common deletion mutation in urine. ART, antiretroviral therapy; ARTRTDFR,
TDF treated; ARTRTDFS, treated with non-TDF therapy; ARTS, antiretroviral naive; CD, common deletion; mtDNA, mito-
chondrial DNA; TDF, tenofovir disoproxil fumarate.Dotted line at5.7 log10 copies/mtDNA corresponds to lower limit of assay.
ND, not detected. Note: On each plot, dots represent individual study participants.count (common deletionþ 577 297 cells/ml, common
deletion 570 308 cells/ml, P¼ 0.9), eGFR (common
deletionþ 93 17, common deletion 96 21, P¼ 0.8),
or TmP/GFR (common deletionþ 0.90 0.31, com-
mon deletion 0.96 0.29, P¼ 0.5). There were trends
toward associations between the presence of the common
deletion and low-nadir CD4þ lymphocyte count
(common deletionþ 145 169, common deletion
250 186, P¼ 0.07) and tubular dysfunction (study
participants with both phosphate and urate wasting;
common deletionþ 5/11, 45%; common deletion 2/21,
10%; P¼ 0.07). Among TDF-treated study participants
there was no effect of pharmacokinetic boosting agents
on the presence of the common deletion. No other large-
scale mtDNA deletions were detectable by long-range
PCR.Discussion
We have studied mtDNA markers in the urine of HIV-
infected study participants, considering both mtDNA
content and mtDNA mutations. First, we have demon-
strated that the measurement of mtDNA from urine is
feasible in the HIV clinic setting. Although mtDNA
depletion has historically been considered the hallmark of
drug-induced mitochondrial dysfunction, this did not
prove a useful marker in this context. This was because
the predominant driver of mtDNA content appeared to
be differences in the cellular composition of urine
samples. An analogous example has been documented in
studies of peripheral blood mtDNA content in sepsis,
where changes in mtDNA content are heavily influenced
by changes in proportions of different leucocyte
populations [17]. Of course, the putative cells of interest
for our study, proximal tubular renal epithelial cells, are
likely to only constitute a minority of the total cellular
population of urine. Ideally, mtDNAwould be examined
in each cell population within urine; however, currently Copyright © 2017 Wolters Kluwer Hreliable methods do not exist for fluorescence-activated
cell sorting of proximal tubule cells from a random
urine sample.
In contrast, we saw a much clearer signal for the mtDNA
common deletion mutation. This assay will not be
significantly affected by changes in the cellular compo-
sition of urine, and can detect mitochondrial damage
which only affects a small subpopulation of cells within
the sample. We saw a clear relationship between the
presence of the common deletion and TDF exposure.
This is the first study to show such an association between
TDF and mtDNA mutations. The assumption is that this
signal is coming from tubular epithelial cells. As described
above, a cell-specific approach such as fluorescence-
activated cell sorting would be required to confirm this
hypothesis. Furthermore, such an approach would allow
us to exclude mtDNA proliferation as a possible
association of deletions. MtDNA deletions are found at
their highest levels in postmitotic tissues such as muscle
and neurons as expansion of deletions occurs within these
cells over time [18]. Within our study, the association
between increased duration of TDF exposure and the
common deletion is in keeping with this notion of
accumulating mutations over time. Once deletions have
formed they tend to persist, even after the causal factor
(including NRTI therapy) has been removed [9]. It will
be important for future studies to address whether these
renal mutations persist after switch from TDF.
Our study has a number of limitations. Given that the
common deletion was seen predominantly in TDF-
treated study participants, we were limited in our power
to detect the effects of other possible factors within this
subgroup. For example, within our data there were
borderline significant associations between the presence
of the common deletion and tubular dysfunction, and
between common deletion and nadir CD4þ lymphocyte
count. The analyses of phosphate biochemistry are
potentially limited by our use of random (unfasted)ealth, Inc. All rights reserved.
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of this study was to provide a proof-of-concept that
mtDNA abnormalities could be detected in routine
clinical samples.
In conclusion, our data demonstrate that mtDNA injury
can be detected in the urine of TDF-treated patients. The
degree to which this may drive TDF-associated renal
pathology merits further investigation. The assessment of
mtDNA mutations, such as the common deletion, in
urine is simple and noninvasive, and potentially scalable to
clinical practice. Further longitudinal studies should be
performed to determine whether this marker of
mitochondrial damage defines a subgroup of TDF-
treated patients who are at risk of clinical renal
complications. Given the recent availability of tenofovir
alafenamide such investigations might in the future help
to prioritize patients for treatment switch.Acknowledgements
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